FDA authorizes second pill against COVID-19 symptoms
Agency approved Molnupiravir one day after approving Pfizer's antiviral pill Paxlovid
Updated: December 23, 2021 - 10:12am
The Facts Inside Our Reporter’s Notebook
The FDA on Thursday authorized a second pill against COVID-19, Merck's Molnupiravir.
The agency approved the drug one day after approving Pfizer's antiviral pill Paxlovid, being prescribed to adults and children 12 and older who have mild to moderate virus symptom and at risk for severe disease or hospitalization, according to a Food and Drug Administration
The ability of Merck's pill to head off severe COVID is much less than initially announced, and the drug's label will warn of serious safety issues including the potential for birth defects, according to the Associated Press.
Just News, No Noise
- CDC issues warning of deadly bacteria with 50% fatality rate coming from the U.S. Gulf Coast
- Wisconsin Congressman says there will be unity for getting Joe Biden out of office
- Marjorie Taylor Greene reveals contents of Biden bribery doc
- Liz Harrington says the American people crave common sense, Trump is top pick
- Plainclothes cops at Capitol during Jan. 6 riot, one on video exhorting crowd, key lawmaker says